CERo Therapeutics upgraded by D. Boral Capital with a new price target
$CERO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
D. Boral Capital upgraded CERo Therapeutics from Hold to Buy and set a new price target of $30.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2025 | $30.00 | Hold → Buy | D. Boral Capital |
D. Boral Capital upgraded CERo Therapeutics from Hold to Buy and set a new price target of $30.00
Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company developing novel T cell therapeutics that incorporate phagocytic mechanisms, announces its shares will be available to trade on the OTCQB market under the ticker symbol CERO effective today, December 2, 2025 as of 8:00AM ET. No action is needed on the part of investors. In the meantime, CERo continues to evaluate additional options for up-list, including, but not limited to listing on a major exchange to optimize liquidity and investor accessibility.
SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces the initiation of the second cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia (AML). The first patient in the cohort (the fourth patient in the trial) received an initial dose of CER-1236 at twice the initial dose of the patients in the first cohort, with a follow-on second identical dose 48 hours later. Stephen Strickland, Jr., M.D., MSCI, director of Leukemia Research for Sarah Cannon Research Institu
Newly released preclinical data to be presented in a poster on November 8, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces it will be presenting data on its lead compound CER-1236 at the Society for Immunotherapy of Cancer (SITC) conference being held November 5-9, 2025 in National Harbor, Md. The poster, titled, "CER-1236, an investigational T cell product targeting TIM-4 Ligand, exhibits sustained effector function and resistance to exhaustion," highlights preclinical data showing the dur
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
DEFA14A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces its Board of Directors has appointed Chris Ehrlich as CEO. Previously he held the position of Interim CEO. Mr. Ehrlich commented, "I believe that CERo presents multiple, significant opportunities to make an impact on the market and benefit a significant patient population with both sound science and an experienced team of professionals to drive successful execution.
SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)